Ribonucleic acids with 4′-thio-modified nucleotides and related methods
View Patent ↗Disclosed are messenger RNA molecules and related compositions incorporating a 4′-thio modification in the furanose ring of at least one nucleotide residue, and methods of using these mRNAs to produce an encoded therapeutic protein in vivo and to treat or prevent diseases or disorders. In certain embodiments, the 4′-thio modified mRNA provides for enhanced stability and/or reduced immunogenicity in in vivo therapies.
1. An mRNA molecule having a coding region and optionally, one or more non-coding regions, wherein at least 25% of the adenosine, at least 25% of the guanosine, at least 25% of the uridine, or at least 25% of the cytidine nucleotide residues of the mRNA incorporate a 4′-thio-substituted furanose ring, wherein the mRNA molecule comprises at least 200 nucleotide residues and wherein up to 20% of the total mRNA nucleotide residues incorporate a 4′-thio-substituted furanose ring, and wherein the mRNA, upon delivery in vivo, produces a protein encoded by the coding region.
2. The mRNA molecule of claim 1 , wherein
at least 25% of the uridine nucleotide residues of the mRNA incorporate a 4′-thio-substituted furanose ring.
3. The mRNA molecule of claim 1 , wherein at least 50% of the uridine residues of the mRNA incorporate a 4′-thio-substituted furanose ring.
4. The mRNA molecule of claim 1 , wherein the non-coding region comprises a poly-A tail, and wherein the poly-A tail comprises 4′-thio-adenosine residues.
5. The mRNA molecule of claim 4 , wherein the poly-A tail is at least about 90 nucleotide residues in length.
6. The mRNA molecule of claim 1 , wherein the mRNA further comprises at least one nonstandard nucleotide residue.
7. The mRNA molecule of claim 6 , wherein the nonstandard nucleotide residue is chosen from one or more of 5-methyl-cytidine, pseudouridine, and 2-thio-uridine.
8. The mRNA molecule according to claim 7 , wherein the one or more non-standard nucleoside residue is further modified to include a 4′-thio-furanose.
9. The mRNA molecule of claim 1 , wherein the molecule comprises at least 500 nucleotide residues.
10. The mRNA molecule of claim 1 , wherein the protein encoded by the coding region is a therapeutic protein.
11. The mRNA molecule of claim 10 , wherein the therapeutic protein is chosen from erythropoietin, human growth hormone, cystic fibrosis transmembrane conductance regulator (CFTR), insulin, alpha-galactosidase A, alpha-L-iduronidase, iduronate-2-sulfatase, N-acetylglucosamine-1-phosphate transferase, N-acetylglucosaminidase, alpha-glucosaminide acetyltransferase, N-acetylglucosamine 6-sulfatase, N-acetylgalactosamine-4-sulfatase, beta-glucosidase, galactose-6-sulfate sulfatase, beta-galactosidase, beta-glucuronidase, glucocerebrosidase, heparan sulfamidase, hyaluronidase, galactocerebrosidase, ornithine transcarbamylase (OTC), carbamoyl-phosphate synthetase 1 (CPS1), argininosuccinate synthetase (ASS1), argininosuccinate lyase (ASL), and arginase 1 (ARG1), glucose-6-phosphatase, glucose-6-phosphate translocase, glycogen debranching enzyme, lysosomal alpha-glucosidase, 1,4-alpha-glucan branching enzyme, glycogen phosphorylase, phosphofructokinase, liver phosphorylase, GLUT-2, UDP glycogen synthase, alpha-L-iduronidase, iduronate sulfate silfatase, heparan sulfate sulfamidase, alpha-N-acetylglucose amidase, alpha-glucosaminid-N-acetyltransferase, N-acetylglucosamine-6-sulfate sulfatase, apolipoprotein E, low density lipoprotein receptor (LDLR), Factor VIII, Factor IX, spinal motor neuron 1 (SMN1), phenylalanine hydroxylase, propionyl-CoA carboxylase, porphobilinogen deaminase, pethylmalonyl-CoA mutase, urate oxidase, C1 esterase inhibitor, and acid alpha-glucosidase.
12. A composition comprising at least one mRNA molecule of claim 1 and a carrier.
13. The composition of claim 12 , wherein the carrier comprises a lipid or a polymer.
14. The composition of claim 13 , wherein the mRNA is encapsulated within a lipid nanoparticle.
15. The composition of claim 12 , wherein the carrier is a lipid nanoparticle that comprises one or more cationic lipids selected from XTC (2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane), MC3 (((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate), ALNY-100 ((3aR,5s,6aS)—N,N-dimethyl-2,2-di((9Z,12Z)-octadeca-9,12-dienyl)tetrahydro-3aH-cyclopenta[d] [1,3]dioxol-5-amine)), NC98-5 (4,7,13-tris(3-oxo-3-(undecylamino)propyl)-N1,N16-diundecyl-4,7,10,13-tetraazahexadecane-1,16-diamide), DODAP (1,2-dioleyl-3-dimethylammonium propane), HGT4003, ICE, HGT5000, cis or trans HGT5001, DOTAP (1,2-dioleyl-3-trimethylammonium propane), DOTMA (1,2-di-O-octadecenyl-3-trimethylammonium propane), DLinDMA, DLin-KC2-DMA, and C12-200.
16. The composition of claim 14 , wherein the lipid nanoparticle comprises one or more helper lipids selected from DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine), DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine), DOPE (1,2-dioleyl-sn-glycero-3-phosphoethanolamine), DPPE (1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine), DMPE (1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine), DOPG (,2-dioleoyl-sn-glycero-3-phospho-(1′-rac-glycerol)), and cholesterol.
17. The composition of claim 14 , wherein the lipid nanoparticle comprises one or more cationic lipids, one or more helper lipids, and a PEGylated lipid.
18. The composition of claim 13 , comprising a polymer that is polyethyleneimine.